Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen’s Blincyto shows efficacy against acute lymphoblastic leukaemia

Amgen’s Blincyto shows efficacy against acute lymphoblastic leukaemia

8th February 2016

Amgen has announced clinical trial results showing the effectiveness of its drug Blincyto among patients with a specific form of leukaemia.

The phase III TOWER study evaluated the efficacy of the drug compared to the current standard of care in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.

Data from a prespecified interim analysis of the phase III trial showed that the primary endpoint of improved overall survival has already been met, with the independent data monitoring committee recommending that the study should end early.

The results of this study will be submitted to a future medical conference and for publication, while Amgen will use the data to support future regulatory filings for Blincyto.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "This is the first study to demonstrate an overall survival benefit for these patients with an immunotherapy, and this is a tremendously rare achievement in relapsed and refractory acute lymphoblastic leukaemia."

The therapy has already been granted breakthrough therapy and priority review designations by the US Food and Drug Administration.ADNFCR-8000103-ID-801812015-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.